Ascendis Health said in a trading update on Wednesday that it was too soon to tell what the financial effect of a rapid increase in demand for chloroquine would be, after the US Food and Drug Administration (FDA) authorised the use of the antimalarial drug for Covid-19.

The group’s Cyprus-based Remedica unit manufactures chloroquine, and while there are no approved treatments for Covid-19, it is being used in emergencies. Chloroquine has been submitted to the FDA for testing to establish long-term efficacy and safety in the US, resulting in a significant increase in demand...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.